Drug intelligence / Profile preview

Tanhuo Wan

Development stage: Unknown
Lead developer: Shanghai Kaibao Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Tanhuo Wan is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanghai Kaibao Pharmaceutical. It is formulated to clear heat, resolve phlegm, and dissipate nodules. Clinically, it is indicated for the treatment of "phlegm-fire" syndromes, which manifest as conditions such as scrofula (cervical lymphadenitis), goiter, and various subcutaneous swellings or hard nodules. The formulation consists of a complex mixture of herbal and mineral ingredients, including *Scrophularia ningpoensis*, *Rehmannia glutinosa*, and *Fritillaria thunbergii*, which work synergistically to cool the blood and soften hardness to reduce swellings.

Brand names: Tanhuo Wan痰火丸
Other names: Tanhuo Pills

Targets

CASP3 (Caspase-3)

Beyond the preview

Go deeper on Tanhuo Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanhuo Wan.

Explore the full profile